Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients

BACKGROUND: The optimal neoadjuvant regimen for locally advanced resectable non-small cell lung cancer (NSCLC) remains controversial. EGFR inhibitors have significantly improved survival in patients with EGFR-mutant advanced NSCLC. However, their efficacy in neoadjuvant settings, particularly for tr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Int Med Res
Main Authors: Xiong, Liwen, Lou, Yuqing, Bai, Hao, Li, Rong, Xia, Jinjing, Fang, Wentao, Zhang, Jie, Han-Zhang, Han, Lizaso, Analyn, Li, Bing, Gu, Aiqin, Han, Baohui
Formato: Artigo
Idioma:Inglês
Publicado em: SAGE Publications 2019
Assuntos:
Prospective Clinical Research Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7607055/
https://ncbi.nlm.nih.gov/pubmed/31885349
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0300060519887275
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados